TY - JOUR AU - Mindy Zambrano Olave AU - Marco Gamarra Contreras PY - 2021/10/05 Y2 - 2024/03/28 TI - FACTORES ASOCIADOS A SEVERIDAD Y MORTALIDAD POR COVID-19 EN PACIENTES CON DIABETES MELLITUS HOSPITALIZADOS; HOSPITAL REGIONAL DEL CUSCO 2020-2021 JF - SITUA JA - SI VL - 24 IS - 2 SE - ARTÍCULOS ORIGINALES DO - 10.51343/si.v24i2.807 UR - https://revistas.unsaac.edu.pe/index.php/SITUA/article/view/807 AB - RESUMENAntecedentes: Ciertas enfermedades infecciosas tienen mayor frecuencia y severidaden pacientes con diabetes, siendo esta una de las comorbilidades más frecuentes de laenfermedad de COVID-19, esta debido a que produce un proceso inflamatorio crónico.Métodos: Estudio de casos y controles, analítico, retrospectivo y transversal, el objetivofue determinar los factores asociados a severidad y mortalidad por COVID-19 enpacientes con diabetes mellitus, se utilizó a toda la población conformada por 76pacientes, de los cuales se hallo 30 casos y 30 controles que cumplian con los criteriosde inclusión, se reviso histórias. Resultados: La mortalidad estuvo asociada a HTA (OR: 1.87; p=0.014; IC 95% [1.14-3.09], dislipidemia (OR: 2.36; p=0.008; [1.25-4.47]),tiempo de evolución de diabetes ≥ 5 años (OR:2.46; p=0.006; IC 95%[1.29-4.70]), nivelde hemoglobina glicosilada entre 7-8.9% (OR:6.61;p=0.000;IC 95% [2.87-15.22] y unnivel ≥9% (OR:3.18; p=0.003; IC95% [1.48-6.81], nivel elevado de PCR (p=0.000) y nivelelevado de LDH(p=0.038) y la severidad estuvo asociada a la severidad estuvo asociadaa HTA (OR:1.69; p=0.029; IC 95% [1.06-2.69]), dislipidemia (OR:1.84; p=0.022; IC 95%[1.09-3.10]), nivel de hemoglobina glicosilada entre 7-8.9% (OR:3.03; p=0.014; IC 95%[1.26-7.31], nivel elevado de glucosa al ingreso (p=0.016), nivel elvado de PCR(p=0.012).Conclusiones: En conclusión se debe prestar especial atención en pacientes condiabetes y COVID-19 que presenten HTA, dislipidemia, tiempo de evolución de diabetes≥ 5 años, nivel elevado de hemoglobina glicosilada, PCR y LDH.Palabras claves: Factores asociados, diabetes mellitus, SARS-CoV-2, mortalidad,enfermedad crítica, muerte por covid-19. [DeCS/MeSH]SUMMARYBackground: Certain infectious diseases are more frequent and severe in patients withdiabetes, this being one of the most frequent comorbidities of the COVID-19 disease, dueto the fact that it produces a chronic inflammatory process. Methods: Analytical,retrospective and cross-sectional case-control study, the objective was to determine thefactors associated with severity and mortality due to COVID-19 in patients with diabetesmellitus, the entire population consisting of 76 patients was used, of which 30 were found.cases and 30 controls that met the inclusion criteria, histories were reviewed. Results:Mortality was associated with hypertension (OR: 1.87; p = 0.014; 95% CI [1.14-3.09],dyslipidemia (OR: 2.36; p = 0.008; [1.25-4.47]), time of evolution of diabetes ≥ 5 years ( OR: 2.46; p = 0.006; 95% CI [1.29-4.70]), glycosylated hemoglobin level between 7-8.9%(OR: 6.61; p = 0.000; 95% CI [2.87-15.22] and a level ≥9% (OR: 3.18; p = 0.003; 95% CI[1.48-6.81], high level of CRP (p = 0.000) and high level of LDH (p = 0.038) and severitywas associated with severity was associated with hypertension (OR : 1.69; p = 0.029;95% CI [1.06-2.69]), dyslipidemia (OR: 1.84; p = 0.022; 95% CI [1.09-3.10]), glycosylatedhemoglobin level between 7-8.9% (OR: 3.03 ; p = 0.014; 95% CI [1.26-7.31], elevatedglucose level upon admission (p = 0.016), elevated CRP level (p = 0.012). Conclusions:In conclusion, special attention should be paid to patients with diabetes and COVID-19who present with hypertension, dyslipidemia, time of evolution of diabetes ≥ 5 years,elevated level of glycosylated hemoglobin, CRP and LDH.Key words: Associated factors, diabetes mellitus, SARS-CoV-2, mortality, criticalillness, death from covid-19. [DeCS/MeSH] ER -